The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
![Australia Australia flag](https://www.greenhill.com/sites/default/files/australia.gif)
illion Australia Pty Ltd
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Experian Plc, the world’s leading global information services company, on the acquisition of illion Australia Pty Ltd, one of Australasia's leading consumer and commercial credit bureaus
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Clinigen Ltd’s portfolio of Established Medicines
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of a portfolio of Established Medicines to CNX Therapeutics, a UK-based European pharma company owned by Inflexion Partners
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Kyowa Kirin International’s testosterone replacement therapy drug, Tostran®
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on the divestiture of its testosterone replacement therapy drug, Tostran®, to Advanz Pharma, a privately-held, specialty pharmaceutical company
![](https://www.greenhill.com/sites/default/files/greece-uk.png)
Clinigen Ltd’s Lamda Laboratories
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Lamda Laboratories, a European contract development business, to Adragos Pharma, a Munich-based pharmaceutical CDMO
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Clinigen Ltd’s Proleukin
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Clinigen Ltd, a UK-based global pharmaceutical services company and portfolio company of Triton Partners, on the sale of Proleukin (Interleukin-2 (Aldesleukin)), to Iovance Biotherapeutics, a late-stage biotechnology company developing novel T cell-based cancer immunotherapies
![](https://www.greenhill.com/sites/default/files/uk-japan.png)
Kyowa Kirin International’s established medicines business
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advising Kyowa Kirin International, a subsidiary of Kyowa Kirin Co., Ltd, a Japanese global specialty pharma company, on a collaboration agreement with Grünenthal GmbH, a global, science-based, privately-owned pharmaceutical company
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Theramex
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Carlyle, the leading private equity investor, on the acquisition of Theramex, a Women’s health-focused specialty pharmaceutical company . The acquisition was jointly executed with PAI Partners
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Acacia Pharma Group plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advising Acacia, a UK-domiciled and Euronext-listed commercial stage biopharmaceutical company, on the sale to Eagle Pharmaceuticals, an integrated pharmaceutical company with R&D, manufacturing and commercial expertise
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Equiniti Group PLC
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Siris Capital, a private equity firm focused on the technology sector, on its recommended 180p cash offer for Equiniti Group PLC, a technology-led services and payments specialist
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Biogix, Inc.
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Biogix, Inc., a leader in the development, research and distribution of clinically tested menopause and perimenopause supplements in the U.S. under the flagship brand Amberen, on its sale to Alliance Pharma plc
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Cello Health plc
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Advised Cello Health, a global healthcare-focused advisory firm, on a recommended cash offer for its entire issued share capital from Arsenal Capital Partners, a specialised private equity firm based in the United States
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advising Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, the largest health insurance provider in the Kingdom of Saudi Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Global rights (excluding North America) to ThermaCare (United Kingdom)
![Italy Italy flag](https://www.greenhill.com/sites/default/files/italy.gif)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the global rights (excluding North America) for ThermaCare, including a dedicated manufacturing facility based in Albany, Georgia, USA, to Angelini Pharma
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Asia and US rights to Physiogel
![South Korea Korea flag](https://www.greenhill.com/sites/default/files/Korea.jpg)
Advised GlaxoSmithKline plc (“GSK”), the UK listed international pharmaceutical and consumer healthcare company, on the divestiture of the rights to Physiogel Asia and the US to Korea-based LG Household & Health Care Ltd
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
TT International
![Japan Japan flag](https://www.greenhill.com/sites/default/files/japan.gif)
Advised TT International, a leading independent asset management firm focused on managing high alpha, high conviction active management strategies for institutional investors, on its sale to Sumitomo Mitsui Financial Group, Inc.
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Pfizer Inc. Consumer Health Business
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised GlaxoSmithKline plc ("GSK"), the UK listed international pharmaceutical and consumer healthcare company, on the combination of GSK's and Pfizer's Consumer Health businesses to create a world-leading Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Assets owned by GlaxoSmithKline plc
![](https://www.greenhill.com/sites/default/files/uk_india_flags.png)
Advised GlaxoSmithKline plc, the UK listed international pharmaceutical and consumer healthcare company, on the divestment of Horlicks and other consumer healthcare nutrition brands to Unilever plc, and on the merger of GSK Consumer Healthcare Limited with Hindustan Unilever Limited
![Switzerland Switzerland flag](https://www.greenhill.com/sites/default/files/switzerland.gif)
Novartis AG’s 36.5% stake in Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised and acted as sponsor to GlaxoSmithKline plc, the UK’s leading pharmaceutical company, on the buyout of Novartis’ 36.5% stake in their Consumer Health Joint Venture
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
London & Country Mortgages Limited (“L&C”)
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Experian plc, the world’s leading global information services company, in connection with the acquisition of a 25% stake in L&C, the UK’s largest fee free mortgage adviser
![United States United States flag](https://www.greenhill.com/sites/default/files/usa_0.gif)
Wells Fargo Share Registration & Service business
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Equiniti Group plc, a UK based specialist technology outsourcer providing non-discretionary payment and administration services, on the acquisition of Wells Fargo's Shareowner Services business, and acted as joint sponsor to Equiniti's associated £122 million rights issue
![Saudi Arabia Saudi Arabia Flag](https://www.greenhill.com/sites/default/files/saudiarabia.gif)
Equity stake in Bupa Arabia
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Advised Bupa, a leading international healthcare group, on the increase of its stake in Bupa Arabia, one of the largest health insurance providers in the Kingdom of Saudi Arabia
![UK/France U.K., France flags](https://www.greenhill.com/sites/default/files/uk_france.gif)
LCH.Clearnet SA
![France France flag](https://www.greenhill.com/sites/default/files/france.gif)
Advised LCH.Clearnet Group Limited, a leading multi-asset class European clearing house, on a sale of LCH.Clearnet SA, its French-regulated operating subsidiary, to Euronext N.V. that was ultimately terminated
![UK/Ireland U.K., Ireland flags](https://www.greenhill.com/sites/default/files/uk-ireland_35558.gif)
Assets and operations of Actavis Generics in the UK and Ireland from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on its sale of assets and operations of Actavis Generics in the UK and Ireland to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited) for £603m (c.$775m)
![Israel Israel flag](https://www.greenhill.com/sites/default/files/israel.gif)
Portfolio of 14 Outlicensing generic products in the EEA from Teva Pharmaceutical Industries Ltd.
![India India flag](https://www.greenhill.com/sites/default/files/india.gif)
Advised Teva Pharmaceutical Industries Ltd., the world’s largest generic drug company, on the divestment of a portfolio of 14 Outlicensing pharmaceutical products in the EEA to Accord Healthcare Ltd. (a subsidiary of Intas Pharmaceuticals Limited).
![United Kingdom United Kingdom flag](https://www.greenhill.com/sites/default/files/uk.gif)
Allied Healthcare
![Germany Germany flag](https://www.greenhill.com/sites/default/files/germany.gif)
Advised Saga plc on the disposal of Allied Healthcare, the leading local authority-funded domiciliary care business in the UK, to AURELIUS Investments